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Background
In contrast to the physiological age related decline of cog-
nitive functions, mild cognitive impairment (MCI) is con-
sidered an early stage of dementia. In the presence of
vascular risk factors, it is difficult to differentiate early
stages of Alzheimer's disease (AD) from those of vascular
dementia (VD), solely on the basis of clinical and neu-
roimaging (CT, MRI) findings. Single photon emission
tomography (SPET) is a technique to obtain functional
tomographic images of the 3-dimensional distribution of
a radiopharmaceutical. One of the most widely used radi-
opharmaceutical for regional Cerebral Blood Flow (CBF)
SPET is Technetium-99m (Tc-99m) labelled compound
with HMPAO (Ceretec; Nycomed Amersham). After intra-
venous injection the Tc-99m-HMPAO lipophilic com-
pound cross the intact blood brain barrier, distribute in
the brain proportional to local blood flow and is retained
in the brain with a fixed regional distribution for a suffi-
cient time period to permit image acquisition. The peak
brain activity is reached within 2 min post-injection. Since
there is no redistribution, the initial tracer uptake and dis-
tribution remains almost unchanged for several hours and
are independent of rCBF variations occurring after the fix-
ation time (frozen images, which represent the rCBF at the
time of injection). Acetazolamide (Diamox) is known to
increase Cerebral Blood Flow (CBF) without changing the
cerebral metabolic rate of oxygen. Patients with compro-
mised circulation and resultant reduced CBF due to
reduced perfusion pressure does not respond to acetazola-
mide. However, little is known about the cerebrovascular
reactivity (CVR) in patients with MCI due to degenerative
or perfusion related memory disturbances.
Materials and methods
This study included 18 patients with demonstrated (clinic
and neuropsychologic findings) MCI. There were ten men
and eight women (age range 52–82 years, mean 69 years)
with neurological clinical examination including Hachin-
ski scale score. Computerized tomography (CT) scanning
and Magnetic resonance (MR) imaging was performed in
all patients. SPET brain perfusion imaging was performed
after the intravenous injection of a typical dose of 740
MBq Tc-99m-HMPAO in two different days before and
after the intravenous administration of 1 gr Diamox. All
SPET scans were interpreted visually.
Results
In 16 of the 18 patients, structural neuroimaging (CT/
MRI) demonstrated the presence of cortical atrophy, and
only two patients presented with relevant signs of ischae-
mic microangiopathy. In contrast, SPET scanning dis-
closed the presence of focal hypoperfusion, indicating the
presence of vascular lesions, in 5 out of 18 patients pre-
sumptive VD group). 12 patients showed the characteris-
tic findings of degenerative dementia (AD), and one
patient was diagnosed as having both signs of focal
ischaemic and global degenerative disease. In the 12
patients with presumptive AD, the mean HS value was
3.5, with a mean HS value of 7.6 in the presumptive VD
group. In the patient with mixed findings, the HS was 6.
Discussion
Applied to the brain, SPET imaging can be used to assess
various functions, among those cerebral perfusion plays a
predominant role. This information is often complemen-
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tary to the anatomic detail provided by structural neu-
roimaging techniques such as CT scanning or MR
imagining. However, brain perfusion SPET has clinical
value itself, because functional impairment in cerebral
diseases often precedes structural changes. Further, func-
tional abnormalities can be present in several neurologic
and psychiatric disorders without the presence of a struc-
tural defect. SPET images are often useful in the clinical
management of patients providing new and additional
information that cannot be obtained from other tech-
niques. Brain perfusion SPET has a role in the diagnosis,
therapeutic management, and follow-up of patients. In
addition it is a useful tool for research, because it is widely
available and provides non invasive in vivo assessment of
human brain function. In patients with MCI, structural
neuroimaging using CT or MRI does not contribute to the
differential diagnosis of presumptive degenerative from
vascular dementia. In contrast, functional imaging of
brain perfusion (and indirectly, metabolism) with
99mTc-HMPAO-SPET detected in all patients the pre-
sumptive underlying disease, either AD, VD or mixed
dementia. SPET findings had a tendency to correlate with
the HS, but the sample size was too small to detect statis-
tical significance. As SP Et al. lows the semi-quantitive
assessment of disease severity (spatial extent and degree of
hypoperfusion), a larger study might allow the correlation
of SPET clinical findings, expressed with neuro-psycho-
logical tests, such as the HS.Page 2 of 2
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